Following innovations
keeping traditions

A unique project

The OncoTarget project includes manufacture of drugs of the most commonly demanded nosological groups in order to carry out state import substitution policy and is designed to arrange for the manufacture of drugs that are not currently produced in the Russian Federation.

The Company's product portfolio includes about 30 types of drugs in various dosage forms planned for manufacture by the end of 2022; these drugs are used to treat oncological, neurological, endocrinological and other high-profile diseases.

Full manufacturing cycle: from substance synthesis to the finished dosage formulations

Compliance with ISO and GMP quality standards

Quality control at every stage of the manufacturing process

Equipment from leading world manufacturers and automation of manufacturing processes

R&D Center

Pharmaceutical development of original, generic and hybrid drugs based on small molecules of chemical origin.

Manufacturing

The manufacturing site in the Technopolis Moscow Special Economic Zone is set up in accordance with ISO and GMP standards and features high-tech imported and domestic equipment from leading global suppliers.

Fully integrated manufacturing

Finished pharmaceutical products

Development of active pharmaceutical substances

OncoTarget independently develops methods of synthesis and technologies to obtain substances intended to manufacture drugs and determine their effectiveness

Active pharmaceutical ingredients

Fully integrated manufacturing

Finished pharmaceutical products

Manufacture of finished pharmaceutical products

Manufacturing of pharmaceutical products to treat high-profile diseases in sterile and non-sterile dosage formulations: solutions in vials, syringes, lyophilizates, tablets and capsules.

Active pharmaceutical ingredients